Edesa Biotech Posts Narrower Loss in Q3

Edesa Biotech (EDSA 1.44%), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, released its fiscal third quarter results on August 8, 2025, covering the period ended June 30, 2025. The company reported a GAAP EPS loss of $(0.25), outperforming the $(0.26) consensus estimate by $0.01, or 3.8% (GAAP). Revenue (GAAP) remained at $0, matching expectations and consistent with its pre-commercial status. Operating expenses (GAAP) held steady ye ...